ARTICLE | Company News
Sorrento, 3SBio in CAR T deal
June 8, 2016 1:06 AM UTC
Sorrento Therapeutics Inc. (NASDAQ:SNRE) said its TNK Therapeutics Inc. subsidiary formed a JV with 3SBio Inc. (HKSE:1530) focused on chimeric antigen receptor T cell therapies.
TNK will grant the JV rights in China, Hong Kong and Macau to CAR T technology targeting carcinoembryonic antigen (CAE)-positive cancers, as well as two additional CARs. 3SBio will contribute $10 million and own 51% of the JV. ...